Abstract

Background: Skin cancer is the most aggressive form of cancer with a high mortality rate. Different medications of skin cancer are accessible, yet because of improvement of multi-drug resistance, flow and rising chemotherapies have a generally low achievement rate. This emphasize the importance of discovering new compounds that are both safe and effective against skin cancer. This study used and compared different routes of administration of a natural compound curcumin to investigate the anti-cancer effect.
 In this investigation it has been resolved that the curcumin expands CAT and SOD levels alongside decline in the TBARS levels.
 Methods: The hindrance of tumour rate Curcumin was assessed in mice on two phase procedure of skin carcinogenesis incited by single utilization of DMBA/7,12-Dimethylbenz[a]-anthracene (100 µg/100 µl of CH3)2CO), and after 2 weeks advanced by rehashed use of croton oil (1% CH3)2CO/thrice in seven days) till the finish of the trial (i.e. 16 weeks). Oral administration of drug at a dose of 500 mg/kg body weight/day at the pre-initiation stage (i.e. 7 days prior and 7 days after DMBA application), promotional stage (for example from the time of croton oil application) and at both the stages (i.e. 7 days before DMBA application and proceeded till the finish of investigation) to the mice Treatment were started 1 week before the exposure to the carcinogen and continued till 25 weeks daily. At the end of experimental period all the animals were sacrificed and observed for various parameters.
 Results: The following parameters (body weight, biochemical studies, haematological studies) were observed and data was collected time to time and calculated statistically to evaluate the anticancer effect of curcumin was found to effective against the skin cancer.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call